Maxime Ronot
@maximeronot
Followers
628
Following
1K
Media
74
Statuses
546
Diagnostic and interventional abdominal radiologist
Paris
Joined May 2009
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy | Targeted and Immune Therapy | JAMA Oncology | JAMA Network
jamanetwork.com
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
0
3
7
🚨EASL CPG on the management of HCC in @JHepatology Major update! ✅ LI-RADS endorsed ✅ Refined treatment algo ✅ More evidence supporting locoregional treatments ✅ Up-to-date discussions 👉 https://t.co/Co4RkGuC1k
journal-of-hepatology.eu
Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers. Advances in diagnostic and...
0
12
41
🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️ ✅Updated advice for managing patients with #HCC & comprehensive review of pertinent data Full text👉 https://t.co/IAMvBDv0CT
#CPGs
#LiverTwitter
@EASLnews
@EASLedu
@AleksanderKrag
1
142
274
🔥off the press: Tumor burden with AFP improves survival prediction for TACE treated patients with HCC @JHEP_Reports
https://t.co/hNo05PURIz 🔎 International observational study 👉Easy to use tool to predict outcome @myESMO @EASLedu @ILCAnews
1
18
48
❕Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study 🔓#OpenAccess at👉 https://t.co/eu79q98Ckz
#LiverTwitter
#HCC
@NaultJc
0
5
14
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology
thelancet.com
Many cancer drugs approved through the FDA's accelerated approval pathway do not offer any survival benefit to patients. In this study, individuals expressed strong preferences for certainty that a...
0
2
10
🩺MRI-assessed intratumoral fat was generally nonprognostic; however, homogeneous intratumoral fat correlated with longer recurrence-free and overall survival in an Asian cohort of hepatocellular carcinoma patients. Findings from @maximeronot! https://t.co/4tIWIsWaP4
0
4
7
Risk of HCC in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound @AGA_CGH
https://t.co/CYDnNHoE63 🔎 Systematic Review, 9 studies, 888 pts 👉risk of HCC: 21.3% 👉risk factors: older age, male sex, elevated AFP, low plts, CP B 🧐repeat ultrasound in 3-6 mo
0
10
33
Read 'open access' at https://t.co/JqSze6d9kQ "Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts" by Mårild et al #GItwitter #IBD
0
2
14
💥EXPERT OPINION Integration of new technologies in the multidisciplinary approach to primary liver tumours ➡️The next-generation tumour board Full text here👉 https://t.co/3fyR1KrxpE
@Naultjc
#LiverTwitter
2
18
31
🔥off the press Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC @JHEP_Reports 🔎🗺️RWD study ❓how to best select for TACE > AFP & Tumor burden 🧐helpful for the discussion in the tumor board 👇my author link: https://t.co/hNo05PURIz
@myESMO
0
13
30
The position paper from EASL about "management of rare primary liver cancers" was recently published in Journal Of Hepatology @EASLnews @JHepatology @campani_claudia @Zucmanrossi @ma5RN
journal-of-hepatology.eu
In recent years, owing to advances in our understanding of hepatocarcinogenesis, rare primary liver cancers (PLCs), including combined hepatocellular-cholangiocarcinoma, fibrolamellar carcinoma, and...
0
14
44
Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… @myESMO #ESMOAmbassadors @ILCA @EASLedu
7
85
183
Congratulations to @F_matteini and team @marco_dioguardi @maximeronot @DrF_Vernuccio for the article "Discontinuous peripheral enhancement of focal liver lesions on CT and MRI: outside the box of typical cavernous hemangioma" published in @Abdominal_Rad 🔗 https://t.co/DlcoXSa78k
0
2
14
🚨 A new episode of the @radiology_rsna podcast is now available! 🚨 @LindaChuMD speaks with Dr. Lorenzo Garzelli and @maximeronot about Predictors of Intestinal Resection–Free Survival after Endovascular Revascularization #RadPodcasts
0
1
6
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies Amazing collective work 💪 Everything there is to know, and more! + a new set of imaging criteria to play with ⬇️ https://t.co/2RRbOgU0k8
@ValdigGroup
@RautouE
0
29
69
@LancetGastroHep @ERN_RARE_LIVER @ValdigGroup 📢The "VALDIG PVT criteria" we propose here will help homogenize studies on portal vein thrombosis in patients without and with cirrhosis ✅agreement > 90 % among 57 international experts‼️
0
5
18
New Review - Elkrief et al - Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies https://t.co/DucWG38nls
@ERN_RARE_LIVER @ValdigGroup #LiverTwitter @RautouE
3
72
152
1/2 Cholangiocarcinoma is a rare but serious liver cancer😕 🇫🇷 French experts have created guidelines to help doctors diagnose and treat it 🔬 Covers risk factors, screening, diagnosis, and treatment options 🔓 https://t.co/7Lnqtbk0uF
#livertwitter
1
58
157